(vi) optionally separating and/or drying the resultant solid material from step (v).

7. A process according to any of claims 1 to 5, wherein the process comprises:

(a) subjecting at least one solid material to mechanical micronization, milling, jet milling, grinding or mixtures thereof;

(b) treating said solid material from step (a) with a non-solvent therefor;

(c) applying ultrasound to the solid material from step (b) when it is in contact with said non-solvent; and

(d) optionally separating and/or drying the resultant solid material from step (c).

8. A process according to any preceding claim, wherein the solid material is a pharmaceutically active ingredient selected from the group consisting of anti-allergics, bronchodilators, anti-inflammatory steroids and mixtures thereof.

9. A process according to any preceding claim, wherein the solid material is a pharmaceutically active ingredient suitable for use in an inhalation formulation, preferably

cromoglycate (*e.g.* as the sodium salt), salbutamol (*e.g.* as the free base or as the sulphate salt), salmeterol (*e.g.* as the xinafoate salt), terbutaline (*e.g.* as the sulphate salt), reproterol (*e.g.* as the hydrochloride salt), beclomethasone dipropionate (*e.g.* as the monohydrate), ~~fluticasone propionate,~~ (-)-4-amino-3,5-dichloro-α-[[[6-[2-(2-pyridinyl)ethoxy]hexyl]amino]-methyl]benzenemethanol, glycopyrronium bromide, darotropium, aclidinium, tiotropium (eg. as bromide salt), theophylline, arofylline, zarfirlukast, montelukast, carmoterol (eg. as the hydrochloride salt), formoterol (eg. as the fumarate salt), or indacaterol and physiologically acceptable salts and solvates thereof, or

carmoterol and physiologically acceptable salts and solvates thereof, or

a combination of carmoterol and physiologically acceptable salts and solvates thereof and a corticosteroid, preferably when the corticosteroid is budesonide, beclomethasone dipropionate, ciclesonide or mometasone, or

glycopyrronium bromide, or

fenoterol, or

a combination of formoterol and a corticosteroid, preferably when the corticosteroid is beclomethasone dipropionate, ciclesonide or mometasone, or

a combination of indacaterol and mometasone, or

a combination of glycopyrronium bromide and indacaterol, or

a combination of tiotropium bromide and formoterol, or

a combination of beclomethasone and salmeterol, or

a combination of ipratropium bromide and albuterol, or

ipratropium, preferably ipratropium bromide, or

darotropium or aclidinium, or

a combination of fenoterol and ipratropium, or

budesonide, salbutamol, formoterol or mixtures of two or more thereof.

~~10. A pharmaceutical or agrochemical composition comprising (i) particles obtained by the process of any preceding claim, and (ii) carrier particles,~~

~~wherein the cohesive-adhesive balance ratio of the particles with the carrier particles is 0.8 to 1.3.~~

~~11. A pharmaceutical or agrochemical composition according to claim 10, wherein the particles have nanometer scale surface corrugations and the value for R_q is between 10 and 100 nm.~~

~~12. A pharmaceutical or agrochemical composition according to any of claims 10 to 11, wherein the surface area of the particles is 6 to 22 m^2/g.~~

~~13. A pharmaceutical or agrochemical composition according to any of claims 10 to 12 wherein the average ratio of the largest diameter of a particle to the smallest diameter of the particle is 1.3-1:1.~~

~~14. A pharmaceutical or agrochemical composition according to any of claims 10 to 13, wherein the carrier particles are selected from lactose, glucose and hydrates thereof.~~

~~15. A dry powder inhaler, a pressurized metered-dose inhaler (pMDI) or a breath activated nasal inhaler containing a pharmaceutical composition according to any of claims 10 to 14.~~